Melatonin modulation of presynaptic nicotinic acetylcholine receptors in the rat vas deferens. 1996

R P Markus, and W M Zago, and R C Carneiro
Department of Pharmacology, Instituto de Ciéncias Biomédicas, Universidade de Säo Paulo, Brazil.

Melatonin, the pineal hormone produced during the dark phase of the light-dark cycle, modulates neuronal acetylcholine receptors located presynaptically on the sympathetic nerve terminals of the rat vas deferens. The pD2 values for nicotine were significantly higher at night (4.20 +/- 0.01) than in the afternoon (3.80 +/- 0.07). Exogenous melatonin shifted the concentration-response curves for nicotine to the left, mimicking the effect of darkness. Melatonin modifies both the displacement and the saturation curves of [3H](-)nicotine binding. In membranes from animals killed at 15:00 h, the binding of [3H](-)nicotine (5-6 nM) was first potentiated and then inhibited by sequential concentrations of (-)nicotine. Higher concentrations of [3H](-)nicotine (50-60 nM) were displaced by all concentrations of nonlabeled ligand. However, when membranes from tissues exposed to melatonin (exogenous or endogenous) were tested, the lower [3H](-)nicotine concentration was displaced progressively by increasing concentrations of nonlabeled ligand. Equilibrium binding studies show a single class of high-affinity nicotinic binding sites with an apparent Kd value of 16 nM and an average maximal number of binding sites of 66 fmol mg-1 protein when animals were killed at the afternoon. Melatonin, although it did not change the properties of high-affinity binding sites, induced the appearance of a second population of lower apparent affinity (Kd = 36.7 nM; Bmax = 185.4 fmol/mg). Melatonin does not modify the functional response and the displacement of [3H](-)nicotine by dimethylphenylpiperazinium. The data suggest that nicotinic neuronal acetylcholine receptors stimulated by dimethylphenylpiperazinium do not change between the light and dark phases. Rather, the higher sensitivity to nicotine in prostatic portions incubated with exogenous melatonin, and in organs from animals killed at night, after the rise of endogenous melatonin, is probably due to the appearance of low-affinity neuronal nicotinic ACh binding sites.

UI MeSH Term Description Entries
D008297 Male Males
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D004246 Dimethylphenylpiperazinium Iodide A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction. DMPP,1,1-Dimethyl-4-phenylpiperazine Iodide,Dimethylphenylpiperazinium,1,1 Dimethyl 4 phenylpiperazine Iodide,Iodide, 1,1-Dimethyl-4-phenylpiperazine,Iodide, Dimethylphenylpiperazinium
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D014649 Vas Deferens The excretory duct of the testes that carries SPERMATOZOA. It rises from the SCROTUM and joins the SEMINAL VESICLES to form the ejaculatory duct. Ductus Deferens,Deferens, Ductus,Deferens, Vas

Related Publications

R P Markus, and W M Zago, and R C Carneiro
November 2005, European journal of pharmacology,
R P Markus, and W M Zago, and R C Carneiro
October 1990, The Journal of pharmacology and experimental therapeutics,
R P Markus, and W M Zago, and R C Carneiro
November 1991, The Journal of pharmacology and experimental therapeutics,
R P Markus, and W M Zago, and R C Carneiro
December 1986, Archives internationales de pharmacodynamie et de therapie,
R P Markus, and W M Zago, and R C Carneiro
January 1983, Life sciences,
R P Markus, and W M Zago, and R C Carneiro
January 1984, Advances in experimental medicine and biology,
R P Markus, and W M Zago, and R C Carneiro
January 1972, Naunyn-Schmiedeberg's archives of pharmacology,
R P Markus, and W M Zago, and R C Carneiro
January 1981, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!